Genmab | GEN - Selling And Administration Expenses


Genmab reported DKK205M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Almirall -29.5M 4.72M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.68B 40M Sep/2026
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Demant DKK 7.09B 1B Jun/2026
Exelixis USD 154.56M 6.93M Sep/2026
Fresenius Medical Care EUR 744M 7.99M Sep/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GN Store Nord DKK 751M 54M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.58B 11M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025